Question 1

What is Krystexxa?

Accepted Answer

Krystexxa is a medication that contains an enzyme used to process uric acid. It works by converting uric acid into a substance called allantoin, which is more easily removed from the body through urine.

By reducing the amount of uric acid circulating in the bloodstream, this therapy helps manage the accumulation of uric acid in the body.

Question 2

What is Krystexxa used for?

Accepted Answer

Krystexxa is used to treat chronic gout refractory to conventional therapy .

Question 3

How does Krystexxa work?

Accepted Answer

Breaking Down Uric Acid

Krystexxa is a type of medication known as a uric acid-specific enzyme. It works by changing uric acid into a different substance called allantoin. Unlike uric acid, which can build up and form crystals in the joints and tissues, allantoin is highly soluble and is easily filtered out of the body by the kidneys.

Targeting Gout Crystals

Gout is caused by high levels of uric acid in the blood, a condition called hyperuricemia. When these levels remain high for a long time, the acid can turn into hard crystals. These crystals lead to the pain, swelling, and joint damage associated with gout. Krystexxa helps by:

Lowering blood levels: It rapidly reduces the amount of uric acid circulating in the bloodstream.

Dissolving deposits: By keeping uric acid levels very low, the medication allows the body to gradually dissolve existing crystal deposits, also known as tophi.

Preventing new crystals: Maintaining low levels helps prevent new crystals from forming in the joints.

This medication is typically used for people with chronic gout whose symptoms have not improved with other standard treatments. Because humans do not naturally produce the enzyme needed to break down uric acid this way, Krystexxa provides a supplemental version of the enzyme to perform this function.

Question 4

What are the active ingredients in Krystexxa?

Accepted Answer

The active ingredient in Krystexxa is pegloticase .

Question 5

What are the side effects of Krystexxa?

Accepted Answer

Common side effects of Krystexxa may include:

gout flare

nausea

bruising

and others

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Krystexxa?

Accepted Answer

Krystexxa belongs to the urate oxidase enzyme drug class.

Question 7

What is the dosage of Krystexxa and how do I take it?

Accepted Answer

How Krystexxa is Given

Krystexxa is administered as an intravenous (IV) infusion into a vein. This procedure is performed by a healthcare professional in a medical setting, such as a clinic or hospital.

Dosing Schedule

The medication is generally given once every two weeks. The infusion process typically takes about two hours to complete. During and after the infusion, healthcare providers will monitor you closely.

Preparation for Treatment

Your healthcare provider may give you other medications before each infusion to help reduce the risk of infusion reactions. These may include antihistamines and corticosteroids. It is important to take these exactly as directed by your doctor.

Missed Doses

If you miss an appointment for your infusion, call your doctor right away to reschedule. It is important to receive each dose as scheduled to manage your condition effectively.

Question 8

Is Krystexxa safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There are no adequate and well-controlled studies of Krystexxa in pregnant women. While animal studies using doses significantly higher than the recommended human dose did not show evidence of harm to the fetus, human data is currently insufficient to determine if there is a drug-associated risk of major birth defects or miscarriage.

Breastfeeding

It is not known whether Krystexxa passes into human breast milk or if it has any effect on a nursing infant or milk production. Because many drugs are excreted in human milk, caution is generally advised when using this medication while nursing.

Consult Your Doctor

If you are pregnant, planning to become pregnant, or are breastfeeding, it is important to discuss the potential benefits and risks of Krystexxa treatment with your healthcare provider. They can help determine the best course of action based on your individual medical needs and the severity of your condition.

Question 9

What forms and strengths does Krystexxa come in?

Accepted Answer

Dosage Forms

Krystexxa is supplied as a sterile, clear, and colorless solution. It is intended for administration through an intravenous infusion after being diluted by a healthcare professional.

The medication is provided in the following format:

Single-dose vial: Each vial contains the medication as a concentrated liquid for one-time use.

Question 10

What is the FDA approval status of Krystexxa?

Accepted Answer

FDA Approval and Indications

Krystexxa (pegloticase) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic gout in adult patients. It is specifically indicated for those with refractory gout, meaning their condition has not responded to or cannot be managed with conventional urate-lowering therapies.

Boxed Warning

The FDA has issued a boxed warning for Krystexxa regarding the risk of serious infusion reactions and anaphylaxis. These reactions can be life-threatening and may occur during or shortly after the administration of the drug. Because of these risks, Krystexxa must only be administered in a healthcare setting by medical professionals who are prepared to manage emergency allergic reactions. Patients are typically pre-medicated with antihistamines and corticosteroids to help reduce the likelihood of these reactions.

Contraindications and Safety Monitoring

The FDA requires specific safety protocols for patients using Krystexxa:

G6PD Deficiency: The medication is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. There is a high risk of hemolysis (the breakdown of red blood cells) and methemoglobinemia in these individuals. Healthcare providers are advised to screen patients at risk for G6PD deficiency before starting treatment.

Uric Acid Levels: Providers must monitor serum uric acid levels before every infusion. A rise in uric acid levels can indicate that the body has developed antibodies against the medication, which increases the risk of a serious infusion reaction.

Regulatory Oversight

The FDA continues to monitor the safety of Krystexxa through post-marketing surveillance. This includes tracking potential signals of serious risks, such as skin and subcutaneous tissue disorders, identified through the FDA Adverse Event Reporting System (FAERS) to ensure ongoing patient safety.

Question 11

What should I know about Krystexxa and cost?

Accepted Answer

Cost Components

Krystexxa is an intravenous (IV) medication administered by a healthcare professional, usually every two weeks. The overall cost is influenced by several factors:

Medication Price: The cost of the drug itself.

Administration Fees: Charges for the healthcare provider's time and the equipment used for the infusion.

Facility Costs: Fees associated with the clinic, hospital, or infusion center where the treatment is given.

Premedications: The cost of medicines like antihistamines and corticosteroids given before the infusion to prevent allergic reactions.

Insurance and Financial Support

Krystexxa is generally covered under the medical benefit portion of insurance plans rather than the pharmacy benefit. Coverage varies based on your specific plan, and most insurers require prior authorization before they will pay for the treatment. Patients with commercial insurance may be eligible for copay assistance programs offered by the manufacturer. For those without insurance or who are underinsured, patient assistance programs may be available to help cover the costs based on financial need.

Krystexxa

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Price Information

FAQ

Found an Error?